Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Transplantation
Volume 2017 (2017), Article ID 3624146, 7 pages
https://doi.org/10.1155/2017/3624146
Case Report

Brincidofovir Use after Foscarnet Crystal Nephropathy in a Kidney Transplant Recipient with Multiresistant Cytomegalovirus Infection

1Centre de Néphrologie et Transplantation Rénale, Hôpital Conception, Assistance Publique-Hôpitaux de Marseille, Marseille, France
2Aix-Marseille University, Marseille, France
3Fédération de Bactériologie-Virologie-Hygiène, Hôpital Timone, Assistance Publique-Hôpitaux de Marseille, Marseille, France
4Laboratoire de Bactériologie-Virologie-Hygiène, Centre Hospitalier Universitaire, Limoges, France
5Pharmacie Hospitalière, Hôpital Conception, Assistance Publique-Hôpitaux de Marseille, Marseille, France
6Laboratoire d’Anatomie Pathologique, Hôpital Timone, Assistance Publique-Hôpitaux de Marseille, Marseille, France

Correspondence should be addressed to Tristan Legris; rf.mh-pa@sirgel.natsirt

Received 26 December 2016; Accepted 12 February 2017; Published 27 February 2017

Academic Editor: Frieder Keller

Copyright © 2017 Romain Vial et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. E. Beam and R. R. Razonable, “Cytomegalovirus in solid organ transplantation: epidemiology, prevention, and treatment,” Current Infectious Disease Reports, vol. 14, no. 6, pp. 633–641, 2012. View at Publisher · View at Google Scholar · View at Scopus
  2. C. N. Kotton, D. Kumar, A. M. Caliendo et al., “Updated international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation,” Transplantation, vol. 96, no. 4, pp. 333–360, 2013. View at Publisher · View at Google Scholar · View at Scopus
  3. R. R. Razonable and A. Humar, “Cytomegalovirus in solid organ transplantation,” American Journal of Transplantation, vol. 13, no. s4, pp. 93–106, 2013. View at Publisher · View at Google Scholar · View at Scopus
  4. P. Ljungman, M. Boeckh, H. H. Hirsch et al., “Definitions of cytomegalovirus infection and disease in transplant patients for use in clinical trials,” Clinical Infectious Diseases, vol. 64, no. 1, pp. 87–91, 2017. View at Publisher · View at Google Scholar
  5. L. Couzi, S. Helou, T. Bachelet et al., “High incidence of anticytomegalovirus drug resistance among D+R− kidney transplant recipients receiving preemptive therapy,” American Journal of Transplantation, vol. 12, no. 1, pp. 202–209, 2012. View at Publisher · View at Google Scholar · View at Scopus
  6. A. K. Le Page, M. M. Jager, J. M. Iwasenko, G. M. Scott, S. Alain, and W. D. Rawlinson, “Clinical aspects of cytomegalovirus antiviral resistance in solid organ transplant recipients,” Clinical Infectious Diseases, vol. 56, no. 7, pp. 1018–1029, 2013. View at Publisher · View at Google Scholar · View at Scopus
  7. R. Lanier, L. Trost, T. Tippin et al., “Development of CMX001 for the treatment of poxvirus infections,” Viruses, vol. 2, no. 12, pp. 2740–2762, 2010. View at Publisher · View at Google Scholar · View at Scopus
  8. E. Justrabo, G. Zanetta, L. Martin et al., “Irreversible glomerular lesions induced by crystal precipitation in a renal transplant after foscarnet therapy for cytomegalovirus infection,” Histopathology, vol. 34, no. 4, pp. 365–369, 1999. View at Publisher · View at Google Scholar · View at Scopus
  9. G. Zanetta, L. Maurice-Estepa, C. Mousson et al., “Foscarnet-induced crystalline glomerulonephritis with nephrotic syndrome and acute renal failure after kidney transplantation,” Transplantation, vol. 67, no. 10, pp. 1376–1378, 1999. View at Publisher · View at Google Scholar · View at Scopus
  10. V. Tischler, M. M. Schuurmans, A. Boehler, and A. Gaspert, “Crystal precipitation and granulomatous inflammation in multiple organs after foscarnet therapy in a lung transplant recipient,” The Journal of Heart and Lung Transplantation, vol. 31, no. 9, pp. 1037–1040, 2012. View at Publisher · View at Google Scholar · View at Scopus
  11. C. Philipponnet, P.-A. Michel, M. Daudon, I. Brocheriou, and J.-J. Boffa, “Intravascular foscarnet crystal precipitation causing multiorgan failure,” American Journal of Kidney Diseases, vol. 65, no. 1, pp. 152–155, 2014. View at Publisher · View at Google Scholar · View at Scopus
  12. D. Iwami, Y. Ogawa, H. Fujita et al., “Successful treatment with foscarnet for ganciclovir-resistant cytomegalovirus infection in a kidney transplant recipient: a case report,” Nephrology, vol. 21, no. S1, pp. 63–66, 2016. View at Publisher · View at Google Scholar · View at Scopus
  13. N. S. Lurain and S. Chou, “Antiviral drug resistance of human cytomegalovirus,” Clinical Microbiology Reviews, vol. 23, no. 4, pp. 689–712, 2010. View at Publisher · View at Google Scholar · View at Scopus
  14. P. West, M. Schmiedeskamp, H. Neeley, J. Oberholzer, E. Benedetti, and B. Kaplan, “Use of high-dose ganciclovir for a resistant cytomegalovirus infection due to UL97 mutation,” Transplant Infectious Disease, vol. 10, no. 2, pp. 129–132, 2008. View at Publisher · View at Google Scholar · View at Scopus
  15. S. Chou, “Phenotypic diversity of cytomegalovirus DNA polymerase gene variants observed after antiviral therapy,” Journal of Clinical Virology, vol. 50, no. 4, pp. 287–291, 2011. View at Publisher · View at Google Scholar · View at Scopus
  16. S. L. Williams-Aziz, C. B. Hartline, E. A. Harden et al., “Comparative activities of lipid esters of cidofovir and cyclic cidofovir against replication of herpesviruses in vitro,” Antimicrobial Agents and Chemotherapy, vol. 49, no. 9, pp. 3724–3733, 2005. View at Publisher · View at Google Scholar · View at Scopus
  17. F. M. Marty, D. J. Winston, S. D. Rowley et al., “CMX001 to prevent cytomegalovirus disease in hematopoietic-cell transplantation,” New England Journal of Medicine, vol. 369, no. 13, pp. 1227–1236, 2013. View at Publisher · View at Google Scholar · View at Scopus
  18. D. El-Haddad, F. El Chaer, J. Vanichanan et al., “Brincidofovir (CMX-001) for refractory and resistant CMV and HSV infections in immunocompromised cancer patients: a single-center experience,” Antiviral Research, vol. 134, pp. 58–62, 2016. View at Publisher · View at Google Scholar
  19. J. F. Camargo, M. I. Morris, L. M. Abbo et al., “The use of brincidofovir for the treatment of mixed dsDNA viral infection,” Journal of Clinical Virology, vol. 83, pp. 1–4, 2016. View at Publisher · View at Google Scholar · View at Scopus
  20. K. M. Mullane, C. Nuss, J. Ridgeway et al., “Brincidofovir treatment of acyclovir-resistant disseminated varicella zoster virus infection in an immunocompromised host,” Transplant Infectious Disease, vol. 18, no. 5, pp. 785–790, 2016. View at Publisher · View at Google Scholar
  21. S. Voigt, J. Hofmann, A. Edelmann, A. Sauerbrei, and J. Kühl, “Brincidofovir clearance of acyclovir-resistant herpes simplex virus-1 and adenovirus infection after stem cell transplantation,” Transplant Infectious Disease, vol. 18, no. 5, pp. 791–794, 2016. View at Publisher · View at Google Scholar
  22. E. Randall Lanier, S. Foster, T. Brundage et al., “Analysis of mutations in the gene encoding cytomegalovirus DNA polymerase in a phase 2 clinical trial of brincidofovir prophylaxis,” Journal of Infectious Diseases, vol. 214, no. 1, pp. 32–35, 2016. View at Publisher · View at Google Scholar · View at Scopus
  23. D. R. Kaul, S. Stoelben, E. Cober et al., “First report of successful treatment of multidrug-resistant cytomegalovirus disease with the novel anti-CMV compound AIC246,” American Journal of Transplantation, vol. 11, no. 5, pp. 1079–1084, 2011. View at Publisher · View at Google Scholar · View at Scopus
  24. G. Deray, F. Martinez, C. Katlama et al., “Foscarnet nephrotoxicity: mechanism, incidence and prevention,” American Journal of Nephrology, vol. 9, no. 4, pp. 316–321, 1989. View at Publisher · View at Google Scholar · View at Scopus
  25. L. Maurice-Estepa, M. Daudon, C. Katlama et al., “Identification of crystals in kidneys of AIDS patients treated with foscarnet,” American Journal of Kidney Diseases, vol. 32, no. 3, pp. 392–400, 1998. View at Publisher · View at Google Scholar · View at Scopus